BMS Keeping A Watchful Eye On Tariffs, Pricing And Other Policy Changes

Q1 Beat Driven By Legacy Drugs, Not Growth Portfolio

 
• By Mandy Jackson
  
BMS updated its guidance to reflect Chinese tariffs on US-manufactured products, but is awaiting updated US policy for further tariff updates (Shutterstock)

More from Earnings

More from Scrip